Bright Green Corporation, a pharmaceutical-grade product provider, has recently broken ground on its $300 million, state-of-the-art cannabis research complex located in Grants, New Mexico. The research complex has been developed with an aim to improve the quality of life for people across demographics through plant-based therapies.
Operating under an MOA (Memorandum of Agreement) with the DEA (Drug Enforcement Administration), Bright Green will offer cannabis and cannabis-related products for research activities in North America. The company has begun the construction phase of the complex, which will become the most advanced cannabis research and manufacturing facility and employ around 100 people. With the business, elected officials, and civic leaders on hand for the occasion, the company officially made New Mexico the home for its premier plant-based research facility.
As per the statement made by Bright Green Corporation’s Chairman, Terry Rafih, the company is thrilled to provide high-quality, plant-based products for therapy research to be conducted by DEA-certified researchers as well as federally authorized Schedule I drug handlers.
For the record, the research complex will feature an advanced agricultural greenhouse ecosystem along with state-of-the-art automation. Additionally, the facility will ensure a consistent supply of cannabinoids and cannabis to the federally licensed researchers, pharmaceutical companies, and universities within the U.S.
Bright Green’s long-term plans, which are compliant with the state, federal, and local government laws, include the construction of an innovative, 115-acre cannabis research and manufacturing complex. Following the completion of the complex construction, it will operate above 7 million sq. ft. of production facilities in New Mexico.
The recent agreement with the DEA allows for the operation and construction of a federally licensed agricultural facility, to expand, distribute, and market marihuana and its chemical constituents to the research entities. Furthermore, the deal will enable Bright Green to supply marihuana and its derivatives for various medical therapies.
The construction of the research complex is slated to be completed in 2023, and will be the most significant, advanced and legally compliant cannabis facility in North America.